Meeting Banner
Abstract #2629

An optimised, MRI-PET based clinical protocol for improving the differential diagnosis of Late-life Depression and Alzheimer's Disease

Louise Emsell1,2,3,4, Kristof Vansteelandt2, François-Laurent De Winter2,4, Filip Bouckaert2,5, Lene Claes4, Danny Christiaens4, Lies Van Assche2,4, Jan Van den Stock2,4, Rik Vandenberghe6, Stefan Sunaert1,3, and Mathieu Vandenbulcke2,4

1Translational MRI, Department of Imaging & Pathology, KU Leuven, Leuven, Belgium, 2Old Age Psychiatry, UPC KU Leuven, Leuven, Belgium, 3Radiology, UZ Leuven, Leuven, Belgium, 4Laboratory for Translational Neuropsychiatry, Dept Neurosciences, KU Leuven, Leuven, Belgium, 5Academisch Centrum voor ECT en Neuromodulatie (AcCENT), UPC KU Leuven, Kortenberg, Belgium, 6Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium

Owing to overlapping symptomatology, differentiating between late-life depression (LLD) and Alzheimer’s Disease (AD), is clinically challenging. Amyloid PET may be used to improve AD diagnosis, however it is expensive and not widely available. Here we apply a two-step MRI driven approach exploiting the different degree of hippocampal volume loss that is present in both disorders to derive hippocampal volume thresholds for identifying patients who could be diagnosed without a PET exam. Using the more cost-effective hippocampal volumetry approach, we could correctly classify half of the patient sample. This increased to 90% when adding 18F-flutametamol PET for the remaining patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here